Captrust Financial Advisors Purchases 308 Shares of Stryker Co. (NYSE:SYK)

Captrust Financial Advisors increased its position in Stryker Co. (NYSE:SYK) by 0.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,272 shares of the medical technology company’s stock after acquiring an additional 308 shares during the quarter. Captrust Financial Advisors’ holdings in Stryker were worth $13,060,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Cary Street Partners Financial LLC bought a new position in Stryker during the fourth quarter worth $3,030,000. Baker Avenue Asset Management LP grew its position in Stryker by 3.6% in the 4th quarter. Baker Avenue Asset Management LP now owns 1,820 shares of the medical technology company’s stock worth $655,000 after purchasing an additional 63 shares during the last quarter. Banque Transatlantique SA acquired a new position in shares of Stryker during the fourth quarter valued at about $45,095,000. Bearing Point Capital LLC bought a new stake in shares of Stryker in the fourth quarter valued at about $6,536,000. Finally, Benjamin Edwards Inc. grew its position in Stryker by 1.0% during the fourth quarter. Benjamin Edwards Inc. now owns 142,039 shares of the medical technology company’s stock worth $51,154,000 after buying an additional 1,363 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Up 1.7 %

SYK opened at $383.84 on Thursday. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The firm has a 50-day moving average price of $365.90 and a two-hundred day moving average price of $374.10. The stock has a market capitalization of $146.51 billion, a PE ratio of 49.46, a PEG ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.73 by $0.11. The firm had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the business posted $2.50 EPS. As a group, equities analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on SYK shares. Royal Bank of Canada raised their price objective on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. Wells Fargo & Company boosted their price target on shares of Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Roth Mkm raised their price objective on shares of Stryker from $405.00 to $456.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. Sanford C. Bernstein set a $450.00 target price on shares of Stryker in a research note on Monday. Finally, Argus set a $450.00 price target on shares of Stryker in a research note on Monday, February 3rd. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $427.05.

Insiders Place Their Bets

In related news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.